bcell maturation antigen bcma bcm also known tumor necrosis factor receptor superfamily member protein humans encoded gene cell surface receptor tnf receptor superfamily recognizes bcell activating factor serum bcell maturation antigen sbcma cleaved form bcma found low levels serum normal patients generally elevated patients multiple myeloma protein encoded gene member tnfreceptor superfamily receptor preferentially expressed mature b lymphocytes may important b cell development autoimmune response receptor shown specifically bind tumor necrosis factor ligand superfamily member lead nfkappab activation receptor also binds various traf family members thus may transduce signals cell survival shown interact bcell activating factor conserved domain nterminus bcma binding domain required binding implicated leukemia lymphomas multiple see mitelman database atlas genetics cytogenetics oncology antibodydrug conjugate belantamab mafodotin evaluated patients relapsedrefractory multiple belantamab mafodotin approved united states august treatment patients relapsed refractory multiple myeloma received least four prior chimeric antigen receptor car cells emerged important therapy multiple myeloma first reports preclinical phase clinical phase study cart cell therapy directed bcma myeloma patients refractory proteasome inhibitor immunomodulatory drug received antibody cart therapy allogene therapeutics targets bcell maturation antigen june undergoing clinical trials treatment multiple april fda granted regenerative medicine advanced therapy status investigated memorial sloan kettering cancer center mayo part universal trial multiple myeloma conjunction selective gamma secretase inhibitor article incorporates text united states national library medicine public domain crystal structure bcma crystal structure april bound bcma httpsenwikipediaorgwikibcellmaturationantigen